Advertisement

Pharmaceutical Research

, Volume 29, Issue 3, pp 643–650 | Cite as

RAB8 Enhances TMEM205-Mediated Cisplatin Resistance

  • Ding-Wu Shen
  • Michael M. Gottesman
Research Paper

ABSTRACT

Purpose

To determine whether the small endosomal recycling GTPase, RAB8, plays a role in TMEM205-associated resistance to the chemotherapeutic drug cisplatin.

Methods

Antibodies were used as markers for both genes; confocal microscopy was used to visualize their localization in cisplatin-resistant cells. Both single and dual-transfections were performed.

Results

Expression of RAB8 was markedly elevated in human cisplatin-resistant cells. We found that TMEM205 was co-localized with RAB8. Dual transfectants with over-expression of both TMEM205 and RAB8 were found to be up to 4-fold more resistant to cisplatin, while cells transfected with RAB8 alone were ~2-fold more resistant.

Conclusions

The development of cisplatin resistance appears to be a consequence of pleotropic epigenetic alterations. We unravel the role of one gene, the GTPase RAB8, in this process. Because its highest expression was at an early step of cisplatin resistance, it may be involved in early development of resistance. Increased expression of TMEM205 and RAB8 in double-transfected cells and their increased resistance to cisplatin indicate an additive effect of these two genes, mediating cisplatin resistance. These two proteins are potential biomarkers or targets for gene or chemotherapy.

KEY WORDS

cisplatin resistance RAB8 TMEM205 

ABBREVIATIONS

DAPI

4′,6-diamidino-2-phenylindole

DMSO

dimethyl sulfoxide

FITC

fluorescein isothiocyanate

GTP

guanosine triphosphate

M6PR

Mannose-6-Phosphate Receptor

miRNA

micro RNA

SDS-PAGE

sodium dodecyl sulfate polyacrylamide gel electrophoresis

STX6

syntaxin 6

TGN

Trans Golgi Network

Notes

ACKNOWLEDGMENTS & DISCLOSURES

This research was funded by the Intramural Research Program of the NIH, Center for Cancer Research, National Cancer Institute. We would like to thank George Leiman for editorial assistance, and Susan Garfield and Poonam Mannan in the Laboratory of Experimental Carcinogenesis (NCI) for assistance with confocal analysis.

REFERENCES

  1. 1.
    Francia G, Man S, Teicher B, Grasso L, Kerbel RS. Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents. Mol Cell Biol. 2004;24:6837–49.PubMedCrossRefGoogle Scholar
  2. 2.
    Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res. 2008;14:1291–5.PubMedCrossRefGoogle Scholar
  3. 3.
    Blair BG, Larson CA, Safaei R, Howell SB. Copper transporter 2 regulates the cellular accumulation and cytotoxicity of Cisplatin and Carboplatin. Clin Cancer Res. 2009;15:4312–21.PubMedCrossRefGoogle Scholar
  4. 4.
    Konkimalla VB, Kaina B, Efferth T. Role of transporter genes in cisplatin resistance. In Vivo. 2008;22:279–83.PubMedGoogle Scholar
  5. 5.
    Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene. 2003;22:7265–79.PubMedCrossRefGoogle Scholar
  6. 6.
    Selvendiran K, Tong L, Vishwanath S, Bratasz A, Trigg NJ, Kutala VK, et al. EF24 induces G2/M arrest and apoptosis in cisplatin-resistant human ovarian cancer cells by increasing PTEN expression. J Biol Chem. 2007;282:28609–18.PubMedCrossRefGoogle Scholar
  7. 7.
    Hall MD, Okabe M, Shen DW, Liang XJ, Gottesman MM. The role of cellular accumulation in determining sensitivity to platinum-based chemotherapy. Annu Rev Pharmacol Toxicol. 2008;48:495–535.PubMedCrossRefGoogle Scholar
  8. 8.
    Shen DW, Su A, Liang XJ, Pai-Panandiker A, Gottesman MM. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer. 2004;91:270–6.PubMedGoogle Scholar
  9. 9.
    Sakai W, Swisher EM, Karlan BY, Agarwal MK, Higgins J, Friedman C, et al. Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers. Nature. 2008;451:1116–20.PubMedCrossRefGoogle Scholar
  10. 10.
    Pogribny IP, Filkowski JN, Tryndyak VP, Golubov A, Shpyleva SI, Kovalchuk O. Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin. Int J Cancer. 2010;127:1785–94.PubMedCrossRefGoogle Scholar
  11. 11.
    Yang H, Kong W, He L, Zhao JJ, O’Donnell JD, Wang J, et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. Cancer Res. 2008;68:425–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Borst P, Jonkers J, Rottenberg S. What makes tumors multidrug resistant? Cell Cycle. 2007;6:2782–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Gottesman MM, Fojo T, Bates SE. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer. 2002;2:48–58.PubMedCrossRefGoogle Scholar
  14. 14.
    Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum-containing cancer drugs. Mol Pharmacol. 2010;77:887–94.PubMedCrossRefGoogle Scholar
  15. 15.
    Wang DS, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov. 2005;4:307–20.PubMedCrossRefGoogle Scholar
  16. 16.
    Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, et al. Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences. Proc Natl Acad Sci USA. 2002;99:16899–903.PubMedCrossRefGoogle Scholar
  17. 17.
    Shen DW, Ma J, Okabe M, Zhang G, Xia D, Gottesman MM. Elevated expression of TMEM205, a hypothetical membrane protein, is associated with cisplatin resistance. J Cell Physiol. 2010;225:822–8.PubMedCrossRefGoogle Scholar
  18. 18.
    Goud B, Gleeson PA. TGN golgins, Rabs and cytoskeleton: regulating the Golgi trafficking highways. Trends Cell Biol. 2010;20:329–36.PubMedCrossRefGoogle Scholar
  19. 19.
    Clark HF, Gurney AL, Abaya E, Baker K, Baldwin D, Brush J, et al. The secreted protein discovery initiative (SPDI), a large-scale effort to identify novel human secreted and transmembrane proteins: a bioinformatics assessment. Genome Res. 2003;13:2265–70.PubMedCrossRefGoogle Scholar
  20. 20.
    Ang AL, Taguchi T, Francis S, Folsch H, Murrells LJ, Pypaert M, et al. Recycling endosomes can serve as intermediates during transport from the Golgi to the plasma membrane of MDCK cells. J Cell Biol. 2004;167:531–43.PubMedCrossRefGoogle Scholar
  21. 21.
    Chabrillat ML, Wilhelm C, Wasmeier C, Sviderskaya EV, Louvard D, Coudrier E. Rab8 regulates the actin-based movement of melanosomes. Mol Biol Cell. 2005;16:1640–50.PubMedCrossRefGoogle Scholar
  22. 22.
    Gerges NZ, Backos DS, Esteban JA. Local control of AMPA receptor trafficking at the postsynaptic terminal by a small GTPase of the Rab family. J Biol Chem. 2004;279:43870–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Huber LA, Dupree P, Dotti CG. A deficiency of the small GTPase rab8 inhibits membrane traffic in developing neurons. Mol Cell Biol. 1995;15:918–24.PubMedGoogle Scholar
  24. 24.
    Kean MJ, Williams KC, Skalski M, Myers D, Burtnik A, Foster D, et al. VAMP3, syntaxin-13 and SNAP23 are involved in secretion of matrix metalloproteinases, degradation of the extracellular matrix and cell invasion. J Cell Sci. 2009;122:4089–98.PubMedCrossRefGoogle Scholar
  25. 25.
    Bravo-Cordero JJ, Marrero-Diaz R, Megias D, Genis L, Garcia-Grande A, Garcia MA, et al. MT1-MMP proinvasive activity is regulated by a novel Rab8-dependent exocytic pathway. EMBO J. 2007;26:1499–510.PubMedCrossRefGoogle Scholar
  26. 26.
    Henry L, Sheff DR. Rab8 regulates basolateral secretory, but not recycling, traffic at the recycling endosome. Mol Biol Cell. 2008;19:2059–68.PubMedCrossRefGoogle Scholar
  27. 27.
    Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol (Toronto, Ont). 2011;18:18–25.Google Scholar
  28. 28.
    Kashiwagi E, Izumi H, Yasuniwa Y, Baba R, Doi Y, Kidani A, et al. Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines. Cancer Sci. 2011;102:382–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Tozawa K, Oshima T, Kobayashi T, Yamamoto N, Hayashi C, Matsumoto T, et al. Oxaliplatin in treatment of the cisplatin-resistant MKN45 cell line of gastric cancer. Anticancer Res. 2008;28:2087–92.PubMedGoogle Scholar
  30. 30.
    Chen S, Liang MC, Chia JN, Ngsee JK, Ting AE. Rab8b and its interacting partner TRIP8b are involved in regulated secretion in AtT20 cells. J Biol Chem. 2001;276:13209–16.PubMedCrossRefGoogle Scholar
  31. 31.
    Ghadially FN, Lock CJ, Yang-Steppuhn SE, Lalonde JM. Platinosomes produced in cultured cells by platinum coordination complexes. J Submicro Cytol. 1981;13:223–30.Google Scholar
  32. 32.
    Murray RZ, Wylie FG, Khromykh T, Hume DA, Stow JL. Syntaxin 6 and Vti1b form a novel SNARE complex, which is up-regulated in activated macrophages to facilitate exocytosis of tumor necrosis Factor-alpha. J Biol Chem. 2005;280:10478–83.PubMedCrossRefGoogle Scholar
  33. 33.
    Zhang Y, Shu L, Chen X. Syntaxin 6, a regulator of the protein trafficking machinery and a target of the p53 family, is required for cell adhesion and survival. J Biol Chem. 2008;283:30689–98.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC (outside the USA) 2011

Authors and Affiliations

  1. 1.Laboratory of Cell Biology, Center for Cancer Research National Cancer InstituteNational Institutes of HealthBethesdaUSA

Personalised recommendations